Effect of recombinant human bone morphogenetic protein-2 and Ling Zhi-8 on osteogenesis: a comparative study using a rabbit sinus model.
OBJECTIVE
This study evaluated the osteogenetic capability of Ling Zhi-8 (LZ-8; a protein purified from traditional Chinese medicine [lingzhi]) compared with recombinant human bone morphogenic protein-2 (rhBMP-2) in a standardized bony defect using a rabbit sinus model.


METHODS
Twelve male New Zealand white rabbits (18 to 24 weeks old, 3.3 to 3.8 kg) were included in the study. Implants of normal saline 0.1 mg, rhBMP-2 0.1 mg, and LZ-8 0.1 mg were each mixed with a uniform biodegradable polyurethane-based material (Nasopore). The implants were inserted in a standardized bony defect of the nasal bone created by a 2.5-mm trephine bur. The rabbits were sacrificed at 1, 2, 4, and 8 weeks postoperatively. Volume computerized tomographic and histomorphometric examinations were used to evaluate the quantity and quality of regenerated bone.


RESULTS
At postoperative week 4, radiography showed that the new bone volume was significantly larger in the rhBMP-2 group compared with the LZ-8 group (P = .041) and the control group (P = .015). Histomorphometrically, better wound healing of the rhBMP-2 group was found during the healing phase compared with the other 2 groups.


CONCLUSIONS
The biomaterial implants using rhBMP-2 and LZ-8 had good biocompatibility and osteogenetic capabilities in the rabbit sinus model. Bone healing in rhBMP-2-treated defects was excellent and showed a significant difference compared with LZ-8. However, LZ-8-treated defects also exhibited bone regeneration, and this traditional Chinese medicine may possess osteogenic potential. Further investigations of the mechanism and application of this protein in osteogenesis are needed.
Attending Surgeon, Oral and Maxillofacial Surgery, Chang Gung Memorial Hospitial, Linkou, Taiwan; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine and Research Center for Biomedical Devices and Prototyping Production, Taipei Medical University, Taipei, Taiwan.
Hsiu-An
HA
Hsu
Attending Surgeon, Division of Oral and Maxillofacial Surgery, Department of Dentistry, Taipei Medical University Hospital, Taipei, Taiwan; and Lecturer, School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Chia-Yu
CY
Wu
Associate Professor, Research Center for Biomedical Devices and Prototyping Production and Graduate Institute of Clinical Medicine and Department of Pathology, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Jan-Show
JS
Chu
Associate Professor, Research Center for Biomedical Devices and Prototyping Production and School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Li-Hsiang
LH
Lin
Undergraduate Student, School of Nutrition and Health Sciences, College of Public Health and Nutrition, Taipei Medical University, Taipei, Taiwan.
Chen-An
CA
Lu
Professor, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Research Center for Biomedical Devices and Prototyping Production, and Research Center for Biomedical Implants and Microsurgery Devices, Taipei Medical University, Taipei, Taiwan; Department of Dentistry, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan. Electronic address: klou@tmu.edu.tw.
Keng-Liang
KL
Ou
D020341:Absorbable Implants; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry; D015519:Bone Density / Q000187:drug effects; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects; D004195:Disease Models, Animal; D004337:Drug Carriers; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005656:Fungal Proteins / Q000627:therapeutic use*; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods; D008297:Male; D009295:Nasal Bone / Q000187:drug effects / Q000601:surgery*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009668:Nose Diseases / Q000601:surgery*; D010012:Osteogenesis / Q000187:drug effects*; D011140:Polyurethanes / Q000737:chemistry; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D004337:Drug Carriers; D004365:Drugs, Chinese Herbal; D005656:Fungal Proteins; D011140:Polyurethanes; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; C061148:LZ-8 protein, Ganoderma lucidum